RSS-Feed abonnieren
DOI: 10.1055/s-0033-1338132
Analysis of Predictive Factors for Postoperative Survival for Non Small Cell Lung Carcinoma Patients with Unexpected Mediastinal Lymph Nodes Metastasis
Publikationsverlauf
09. November 2012
06. Februar 2013
Publikationsdatum:
12. April 2013 (online)
![](https://www.thieme-connect.de/media/thoracic/201402/lookinside/thumbnails/10.1055-s-0033-1338132-1.jpg)
Abstract
Objectives To discuss the predictive factors of postoperative survival for non small cell lung carcinoma (NSCLC) patients with clinical N0 stage but postoperative pathological N2 stage (cN0–pN2).
Methods From January 1, 2005, to December 31, 2009, the clinical data of NSCLC patients with cN0–pN2 after radical surgery were retrospectively collected, and their survival information was collected through follow-up. The expiration date for follow-up was December 31, 2011. The predictive factors of postoperative survival for NSCLC patients with unexpected mediastinal lymph node metastasis were analyzed using Cox proportional hazards regression.
Results A total of 263 patients were enrolled. The follow-up rate was 91.63%. The overall 1-, 3-, and 5-year survival rates were 94.6, 55.2, and 26.3%, respectively. Video-assisted thoracotomy surgery (VATS; odds ratio [OR] 0.659; 95% confidence interval [CI] 0.469 to 0.927; p = 0.017), multiple stations of metastatic mediastinal lymph nodes (OR 1.605; 95% CI 1.180 to 2.183; p = 0.003), and no adjuvant chemotherapy (OR 1.576; 95% CI 1.105 to 2.246; p = 0.012) were independent predictive factors for unexpected N2 patients. The median survival after VATS was superior to that after thoracotomy for patients with a single station of metastatic mediastinal lymph node (48.45 m vs 37.34 m, p = 0.018). The median survival without any adjuvant chemotherapy was inferior to that after adjuvant chemotherapy for patients with multiple stations of metastatic mediastinal lymph nodes (20.32 m vs 31.55 m, p = 0.001).
Conclusion The postoperative survival for NSCLC patients with cN0–pN2 was related to operational method, adjuvant chemotherapy, and the number of metastatic mediastinal lymph node stations. Patients with a single station of metastatic mediastinal lymph node are likely to benefit from VATS, whereas patients with multiple stations of metastatic mediastinal lymph nodes are likely to benefit from adjuvant chemotherapy.
-
References
- 1 Decaluwé H, De Leyn P, Vansteenkiste J , et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009; 36 (3) 433-439
- 2 Kim HK, Choi YS, Kim J, Shim YM, Kim K. Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 2010; 140 (6) 1288-1293
- 3 Iskender I, Kapicibasi HO, Kadioglu SZ , et al. Comparison of integrated positron emission tomography/computed tomography and mediastinoscopy in mediastinal staging of non-small cell lung cancer: analysis of 212 patients. Acta Chir Belg 2012; 112 (3) 219-225
- 4 Lee BE, Kletsman E, Rutledge JR, Korst RJ. Utility of endobronchial ultrasound-guided mediastinal lymph node biopsy in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 2012; 143 (3) 585-590
- 5 Nakanishi R, Osaki T, Nakanishi K , et al. Treatment strategy for patients with surgically discovered N2 stage IIIA non-small cell lung cancer. Ann Thorac Surg 1997; 64 (2) 342-348
- 6 Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 2008; 86 (2) 362-366 , discussion 366–367
- 7 Detterbeck F. What to do with “Surprise” N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 2008; 3 (3) 289-302
- 8 Lorent N, De Leyn P, Lievens Y , et al; Leuven Lung Cancer Group. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004; 15 (11) 1645-1653
- 9 Riquet M, Hidden G, Debesse B. Direct lymphatic drainage of lung segments to the mediastinal nodes. An anatomic study on 260 adults. J Thorac Cardiovasc Surg 1989; 97 (4) 623-632
- 10 Riquet M, Assouad J, Bagan P , et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg 2005; 79 (1) 225-233
- 11 Junker K, Gumprich T, Müller KM. Diskontinuierliche Lymphknotenmetastasen (“skipping”) bei bösartigen Lungentumoren. [Discontinuous lymph node metastases (“skipping”) in malignant lung tumors]. Chirurg 1997; 68 (6) 596-599, discussion 600
- 12 Friedel G, Linder A, Pfeiffer S, Toomes H. Radical lung surgery interventions with special reference to lymphadenectomy. Langenbecks Arch Chir Suppl Kongressbd 1996; 113: 785-789
- 13 Sugi K, Kaneda Y, Esato K. Video-assisted thoracoscopic lobectomy achieves a satisfactory long-term prognosis in patients with clinical stage IA lung cancer. World J Surg 2000; 24 (1) 27-30 , discussion 30–31
- 14 Gabor S, Renner H, Popper H , et al. Invasion of blood vessels as significant prognostic factor in radically resected T1–3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2008; 34 (4) 892-897
- 15 Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients. Thorax 2010; 65 (12) 1092-1098
- 16 Lee AK, DeLellis RA, Silverman ML, Heatley GJ, Wolfe HJ. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 1990; 8 (9) 1457-1465
- 17 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350 (4) 351-360
- 18 Pignon J-P, Tribodet H, Scagliotti GV , et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21) 3552-3559
- 19 Winton T, Livingston R, Johnson D , et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352 (25) 2589-2597
- 20 Waller D, Peake MD, Stephens RJ , et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26 (1) 173-182
- 21 Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest 2006; 130 (6) 1791-1795
- 22 Sawhney MS, Bakman Y, Holmstrom AM, Nelson DB, Lederle FA, Kelly RF. Impact of preoperative endoscopic ultrasound on non-small cell lung cancer staging. Chest 2007; 132 (3) 916-921